In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi

被引：57

作者：

Biswas, Chayanika ^{[1
]}

Law, Derek ^{[2
]}

Birch, Michael ^{[2
]}

Halliday, Catriona ^{[1
]}

Sorrell, Tania C. ^{[3
]}

Rex, John ^{[2
]}

Slavin, Monica ^{[4
,5
]}

Chen, Sharon C-A ^{[1
]}

机构：

[1] Westmead Hosp, New South Wales Hlth Pathol, Inst Clin Pathol & Med Res, Ctr Infect Dis & Microbiol Lab Serv, Sydney, NSW, Australia

[2] F2G Ltd, Manchester, Lancs, England

[3] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia

[4] Victorian Comprehens Canc Ctr, Melbourne, Vic, Australia

[5] Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia

来源：

MEDICAL MYCOLOGY | 2018年 / 56卷 / 08期

关键词：

Scedosporium; Lomentospora; antifungal susceptibility; F901318; orotomide; SUSCEPTIBILITY; ASPERGILLUS; FUSARIUM; VORICONAZOLE; GUIDELINES; AGENTS; MOLDS;

D O I：

10.1093/mmy/myx161

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We determined the in vitro activity of the novel orotomide antifungal, F901318, against 30 Lomentospora prolificans, 20 Scedosporium apiospermum, 7 S. aurantiacum, and 3 S. boydii, isolates in comparison with standard antifungals. Against L. prolificans, F901318 was the most potent compound (MIC90 0.25 mu g/ml); the geometric mean MIC (0.26 mu g/ml) was significantly lower (23-80-fold) than those of itraconazole, voriconazole, posaconazole, and isavuconazole (all P < .001), and amphotericin B (P < .05). F901318 also had good activity against S. apiospermum, S. aurantiacum, and S. boydii, comparable to that of voriconazole and posaconazole but was more active than isavuconazole for all three species.

引用

页码：1050 / 1054

页数：5

共 50 条

[1] Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans
Wiederhold, Nathan P.
Law, Derek
Birch, Michael
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (07) : 1977 - 1980
[2] Activity of orotomide F901318 against clinical isolates of Scedosporium spp. and Lomentospora prolificans
Alastruey Izquierdo, A.
Rivero-Menendez, O.
MYCOSES, 2017, 60 : 211 - 211
[3] In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates
Buil, J. B.
Rijs, A. J. M. M.
Meis, J. F.
Birch, M.
Law, D.
Melchers, W. J. G.
Verweij, P. E.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (09) : 2548 - 2552
[4] Molecular identification of Scedosporium species from CF patients and in vitro susceptibility of the novel antifungal compound F901318
Meis, J. F.
Steeghs, D.
Hagen, F.
Chowdhary, A.
Verweij, P. E.
MYCOSES, 2017, 60 : 78 - 79
[5] In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus
Kirchhoff, Lisa
Dittmer, Silke
Buer, Jan
Rath, Peter-Michael
Steinmann, Joerg
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (03)
[6] In Vitro Activity of the Novel Antifungal Olorofim against Scedosporium and Lomentospora prolificans
Georgacopoulos, Ourania
Nunnally, Natalie
Law, Derek
Birch, Mike
Berkow, Elizabeth L. L.
Lockhart, Shawn R. R.
MICROBIOLOGY SPECTRUM, 2023, 11 (01):
[7] In vitro activity of F901318 against filamentous fungi from cystic fibrosis patients
Seufert, R.
Dittmer, S.
Heep, M.
Rath, P. M.
Steinmann, J.
MYCOSES, 2018, 61 : 14 - 15
[8] In vitro activity of F901318 against filamentous fungi from cystic fibrosis patients
Steinmann, J.
Dittmer, S.
Heep, M.
Rath, P-M.
MEDICAL MYCOLOGY, 2018, 56 : S83 - S83
[9] Review of the novel antifungal drug olorofim (F901318)
Vanbiervliet, Yuri
Van Nieuwenhuyse, Tine
Aerts, Robina
Lagrou, Katrien
Spriet, Isabel
Maertens, Johan
BMC INFECTIOUS DISEASES, 2024, 24 (01)
[10] Correction: Review of the novel antifungal drug olorofim (F901318)
Yuri Vanbiervliet
Tine Van Nieuwenhuyse
Robina Aerts
Katrien Lagrou
Isabel Spriet
Johan Maertens
BMC Infectious Diseases, 24 (1)

← 1 2 3 4 5 →